Rebecca Moran
Physician Assistant · Newnan, GANPI 1750045373
Payments from drug & device makers
Across 101 payments — averaging $23.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$214
- Novartis$182
- AstraZeneca$176
- Johnson & Johnson$144
- Sobi, Inc$127
- Gilead$112
- plus $1K from 34 others
What the payments were for
- Food & beverage$2,15589%
- Education$26511%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 8 | $214 |
| Novartis | 7 | $182 |
| AstraZeneca(2 entities) | 8 | $176 |
| Johnson & Johnson | 4 | $144 |
| Sobi, Inc | 3 | $127 |
| Gilead(2 entities) | 2 | $112 |
| Eisai Inc. | 6 | $106 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $91 |
| Bristol Myers Squibb | 4 | $83 |
| Lilly USA, LLC | 4 | $82 |
| Bayer | 5 | $77 |
| Beone Medicines USA, Inc. | 3 | $75 |
| Beigene USA, Inc. | 3 | $68 |
| Incyte Corporation | 3 | $67 |
| Genentech USA, Inc. | 3 | $67 |
| Merck | 3 | $65 |
| Stemline Therapeutics Inc. | 3 | $65 |
| Exelixis Inc. | 3 | $59 |
| AbbVie | 3 | $48 |
| AVEO Pharmaceuticals, Inc. | 2 | $48 |
| Foundation Medicine, Inc. | 2 | $44 |
| Jazz Pharmaceuticals Inc. | 1 | $32 |
| Tersera Therapeutics LLC | 1 | $32 |
| Taiho Oncology, Inc. | 1 | $30 |
| Regeneron Healthcare Solutions, Inc. | 1 | $28 |
| Ipsen Biopharmaceuticals, Inc | 1 | $25 |
| Blueprint Medicines Corporation | 1 | $23 |
| Mirati Therapeutics, Inc. | 1 | $23 |
| Seagen Inc. | 1 | $22 |
| Verity Pharmaceuticals Inc. | 1 | $22 |
| Acrotech Biopharma Inc. | 1 | $21 |
| Rigel Pharmaceuticals, Inc. | 1 | $21 |
| Karyopharm Therapeutics Inc. | 1 | $21 |
| Deciphera Pharmaceuticals Inc. | 1 | $20 |
| Pfizer | 1 | $19 |
| Legend Biotech USA Inc. | 1 | $17 |
| Puma Biotechnology, Inc. | 1 | $17 |
| Amgen | 1 | $16 |
| Fennec Pharmaceuticals, Inc. | 1 | $15 |
| ADC Therapeutics America, Inc. | 1 | $14 |
How this compares
$2,420 in reported general payments places this provider in the 80th percentile of 3,581 physician assistant providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other physician assistant in Newnan
- Onyebuchi NeitaNewnan$47K
- Norman GibbyNewnan$19K
- Douglas DiruggieroCartersville$1.3M
- Jennifer CobbsAtlanta$1M
- A BrunnerStockbridge$1M
- Joseph LangshawCalhoun$887K
- Alison MoeAtlanta$410K
- Maggie SchreckAtlanta$389K
- Lisa HillMarietta$190K
- Laura BishopBrunswick$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.